Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients
Condition: Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics Interventions: Drug: Empagliflozin; Drug: olanzapine Sponsor: Tanta University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 3, 2023 Category: Research Source Type: clinical trials
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
Conditions: End-stage Kidney Disease; Kidney Disease, Chronic; Dialysis; Diabetic; Non-diabetic; Kidney Dysfunction; Kidney Failure; Hemodialysis Interventions: Drug: Empagliflozin; Other: Placebo Sponsors: University of Utah; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 14, 2022 Category: Research Source Type: clinical trials
